Home
News
Videos
Podcasts
Menu
Акционерное общество "ТВ БРИКС"
tvbrics@tvbrics.com
Рубцов переулок, д.13, Москва, 105082, RU
+74996425304
Currencies:
RUB/USD 0,0124
BRL/USD 0,1861
INR/USD 0,0105
CNY/USD 0,15
ZAR/USD 0,0601
IDR/USD 0,0001
SPACE FOR MEDIA DIPLOMACY
21:30 «Nature reserves of the Russian Federation»
21:30 «Nature reserves of the Russian Federation»
Now 16+
21:30

«Nature reserves of the Russian Federation»

It is indicated Moscow time in the programme. Please take into account the time difference with your time zone.
22:00 «City of stories»
Next
22:00

«City of stories»

16+
22:30

«In the Rhythm of BRICS»

12+
23:00

«BRICSreport»

16+
Menu
Broadcast «Nature reserves of the Russian Federation»
RUB/USD
0,0124
↑
BRL/USD
0,1861
↑
INR/USD
0,0105
↑
CNY/USD
0,15
↑
ZAR/USD
0,0601
↑
IDR/USD
0,0001
↑
TV BRICS Apps

India aims for global chemical sector growth with bio-pharma focus

New Delhi sets sights on 5–6 per cent global market share by 2030 and US$1 trillion turnover by 2040, emphasising innovation and biosimilars


India’s chemical industry is poised for a major leap in the coming decade, with the government projecting a rise in its global sector share to 5–6 per cent by 2030 and targeting a US$1 trillion turnover by 2040. The strategy prioritises biologics, biosimilars, and innovation-driven growth, alongside the establishment of advanced chemical infrastructure, reports IANS, a partner of TV BRICS.

Union Minister Jagat Prakash Nadda highlighted that by 2035, 40 per cent of medicines worldwide are expected to be biologics, and India is committed to meeting this issue through dedicated research, regulatory support, and infrastructure development.

The plan includes developing 1,000 clinical trial sites nationwide to boost research capacity while strengthening national institutions to ensure faster approvals and greater innovation. Three new world-class chemical parks will address infrastructural gaps, integrating plug-and-play utilities, advanced effluent treatment, and circular economy principles, potentially reducing operational costs by up to 40 per cent.

Experts note that even a 1 per cent share of the global biosimilars market could translate into an annual opportunity worth approximately US$22 billion.

This strategic focus on high-value biologics and biosimilars, combined with advanced infrastructure and regulatory support, signals India’s ambition to transform from a domestic sector into a leading global player in chemicals and pharmaceuticals.